Yhdysvallat - englanti - NLM (National Library of Medicine)

wg critical care, llc - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dextrose monohydrate 5000 mg in 100 ml - 5% dextrose injection is indicated as a source of water and calories.

Yhdysvallat - englanti - NLM (National Library of Medicine)

baxter healthcare corporation - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - dextrose injection is indicated as source of water and calories. the use of dextrose injection is contraindicated in patients with: risk summary appropriate administration of dextrose injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with injectable dextrose solutions. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of dextrose in human milk, the effects on a breastfed infant, or the effects on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of dextrose injection to

Yhdysvallat - englanti - NLM (National Library of Medicine)

hospira, inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 50% dextrose injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. the solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. slow infusion of hypertonic solutions is essential to ensure proper utilization of dextrose and avoid production of hyperglycemia. a concentrated dextrose solution should not be used when intracranial or intraspinal hemorrhage is present, nor in the presence of delirium tremens if the patient is already dehydrated. dextrose injection without electrolytes should not be administered simultaneously with blood through the same infusion set because of the possibility that pseudoagglutination of red cells may occur.

Yhdysvallat - englanti - NLM (National Library of Medicine)

laboratorios alfa srl - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 5% dextrose solution is indicated as a source of water and calories. it is used to decrease the excessive pressure of spinal brain fluid, also as sclerosing to treat varicose veins and decrease intracranial pressure this is a single dose container and does not contain preservatives. use the solution immediately after the bottle is opened, discard the remaining one. squeeze and inspect the bottle, discard if leaks are found or if the solution contains visible and solid particles. do not administer simultaneously with blood. do not use it unless solution is clear, and seal is intact. directions for use plastic container: this is a single dose container and does not contain preservatives. if leaks are found, discard solution as sterility may be impaired. use the solution immediately after the bottle is opened, discard the remaining one. discard unused portion. if supplemental medication is desired follow directions below: preparation and administration 1. check for minute leaks by squeezing the container firmly. if leaks are found, discard solution as sterility may be impaired. 2. suspend container from eyelet support. 3. remove plastic protector from ports area at the bottom of container. 4. hold the bottle in vertical position and inset pyrogen free iv administration set in the outlet port. use aseptic technique to add medication warning: additives may be incompatible. to add medication before solution administration 1. prepare medication site. 2. using syringe with 19 to 22 gauge needle, puncture inlet port and inject. 3. mix solution and medication thoroughly. for high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly. to add medication during solution administration 1. close clamp on the set. 2. prepare medication site. 3. using syringe with 18 to 21 gauge needle, puncture inlet port and inject. 4. remove container from iv pole and/or turn to an upright position. 5. mix solution and medication thoroughly. 6. return container to in use position and continue administration. caution: federal law (usa) restricts this drug to use by or on the order of a licensed veterinarian.

Yhdysvallat - englanti - NLM (National Library of Medicine)

laboratorios alfa srl - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 10% dextrose dolution has value as a source of water and calories. it is used to decrease the excessive pressure of spinal brain fluid, also a scloerisng to treat varicose veins and decrease intracranial pressure. this is a single dose container and does not contain preservatives. use the solution immediately after the bottle is opened, discard the remaining one. squeeze and inspect the bottle, discard if leaks are found or if the solution contains visible and solid particles. do not administer simultaneously with blood. do not use it unless solution is clear, and seal is intact. preparation and administration 1. check for minute leaks by squeezing the container firmly. if leaks are found, discard solution as sterility may be impaired. 2. suspend container from eyelet support. 3. remove plastic protector from ports area at the bottom of container. 4. hold the bottle in vertical position and inset pyrogen free iv administration set in the outlet port. use aseptic technique to add medication warning: additives may be incompatible. to add medication before solution administration 1. prepare medication site. 2. using syringe with 19 to 22 gauge needle, puncture inlet port and inject. 3. mix solution and medication thoroughly. for high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly. to add medication during solution administration 1. close clamp on the set. 2. prepare medication site. 3. using syringe with 18 to 21 gauge needle, puncture inlet port and inject. 4. remove container from iv pole and/or turn to an upright position. 5. mix solution and medication thoroughly. 6. return container to in use position and continue administration. caution: federal law (usa) restricts this drug to use by or on the order of a licensed veterinarian.

Yhdysvallat - englanti - NLM (National Library of Medicine)

icu medical inc. - dextrose monohydrate (unii: lx22yl083g) (anhydrous dextrose - unii:5sl0g7r0ok) - 10% dextrose injection is indicated for admixture with amino acids or dilution with other compatible iv fluids to provide a 5% final dextrose concentration for intravenous infusion in patients whose condition requires parenteral nutrition. the use of 10% dextrose injection is contraindicated in patients with: - clinically significant hyperglycemia [see warnings and precautions (5.1)] . - known hypersensitivity to dextrose [see warnings and precautions (5.2)] . risk summary appropriate administration of dextrose injection during pregnancy is not expected to cause adverse developmental outcomes, including congenital malformations. animal reproduction studies have not been conducted with injectable dextrose solutions. the estimated background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively risk summary there are no data on the presence of dextrose in human milk, the effects on a breastfed infant, or the effects on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of dextrose injection to an infant during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for dextrose injection and any potential adverse effects on the breastfed infant from dextrose injection or from the underlying maternal condition. the safety profile of dextrose injection in pediatric patients is similar to adults. neonates, especially premature infants with low birth weight, are at increased risk of developing hypo-or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose infusions to ensure adequate glycemic control in order to avoid potential long-term adverse effects. closely monitor plasma electrolyte concentrations in pediatric patients who may have impaired ability to regulate fluids and electrolytes. in very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and risk of intracerebral hemorrhage. children (including neonates and older children) are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy [see warnings and precautions (5.4)]. because of immature renal function, preterm infants receiving prolonged treatment with dextrose injection, may be at risk aluminum toxicity [see warnings and precautions (5.6)] . clinical studies of dextrose injection did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. elderly patients are at increased risk of developing hyponatremia as well as for developing hyponatremic encephalopathy [see warnings and precautions (5.4)] . other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. dextrose is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

qatar pharma, qatar - dextrose - solution for infusion - 25 %

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

qatar pharma, qatar - dextrose - solution for infusion - 25 %

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose - solution for injection - 10 %

Saudi-Arabia - englanti - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

pharmaceutical solution industries (psi), saudi arabia - dextrose - solution for injection - 10 %